SCHEMBL29186539

SCHEMBL29186539

CNC(=O)c1ccc2nccc(Oc3cc(OC)cc(-n4cccn4)c3)c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 3/20 0.50
▸ AXL P30530 2/20 0.50
▸ MERTK Q12866 2/20 0.50
▸ DDR2 Q16832 1/20 0.50
▸ KAT6A Q92794 2/20 0.44
▸ CYP1A2 P05177 2/20 0.44
▸ CYP2C19 P33261 2/20 0.44
▸ ICAM1 P05362 1/20 0.44
▸ SELE P16581 1/20 0.44
▸ VCAM1 P19320 1/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ KDR P35968 3/20 0.44
▸ HPGD P15428 2/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ LCK P06239 1/20 0.44
▸ TEK Q02763 1/20 0.44
▸ AURKB Q96GD4 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30050388 1.00 MET (0.50) METAXLMERTKDDR2KAT6A
SCHEMBL29321845 0.91 MET (0.49) METAXLMERTKDDR2CYP1A2
SCHEMBL29186571 0.90 DDR2 (0.52) METAXLMERTKDDR2KAT6A
SCHEMBL30049913 0.89 DDR2 (0.49) METAXLMERTKDDR2KAT6A
SCHEMBL29186536 0.89 DDR2 (0.49) METAXLMERTKDDR2KAT6A
SCHEMBL29317904 0.86 AXL (0.54) METAXLMERTKDDR2KDR
SCHEMBL30051321 0.86 AXL (0.54) METAXLMERTKDDR2KDR
SCHEMBL30049315 0.84 DDR2 (0.56) DDR2KDM4EKDRPDGFRA
SCHEMBL29317844 0.84 DDR2 (0.56) DDR2KDM4EKDRPDGFRA
SCHEMBL29318171 0.82 DDR2 (0.47) DDR2KDRPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CHENGDU ANTICANCER BIOSCIENCE LTD (CN) 2024-07-18 — — US disclosed
CN-117321036-A phenyl-O-quinoline, quinazoline, thienopyridine, thienopyrimidine, pyrrolopyridine, pyrrolopyrimidine compounds having anticancer activity 成都安泰康赛生物科技有限公司 2023-12-29 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239806-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS CYP27A1, CPT1A, OAT MET 4678/4885AXL 4879/4885MERTK 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback